Study Exclusion reasons Remarks Reference(s)
O'Brien (Part A: uninfected household contacts), 2021 randomized controlled trial < Study carried out before the release of the omicron variant >

O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569

O'Brien MP et al. New England Journal of Medicine 10.1056/NEJMoa2109682

O?Brien MP et al. medRxiv 10.1101/2021.06.14.21258567

 
O'Brien (Part B: recently infected asymptomatic patients), 2021 randomized controlled trial

O'Brien MP et al. medrxiv;2021.06.14.21258569v1 10.1101/2021.06.14.21258569

 
CT-P59 1.2, 2020 randomized controlled trial no clinically relevant endpoint preliminary unpublished results extracted from the EMA review document. < Study carried out before the release of the omicron variant >  
Isa, 2021 randomized controlled trial other Phase I: multiple-dose administration of REGEN-COV.

Isa F et al. medRxiv 10.1101/2021.11.10.21265889